Optimum Perspectives Optimum Strategic Communications

Diverse recruitment for clinical trials is a huge issue – but what can drug developers do to overcome this challenge? Join Optimum’s Richard Staines as he discuses this thorny issue with Ariceum Therapeutic’s CMO, Germo Gericke, Leucid Bio’s CSO, John Maher and Non-Executive Director & Thought Leader Annalisa Jenkins.
Hosted on Acast. See acast.com/privacy for more information.

Following recent encouraging interim clinical results, hear Øystein Rekdal, CEO of Lytix Biopharma, discuss with Optimum's Nick Bastin how the company's lead candidate LTX-315 has a unique approach to killing cancer.
Hosted on Acast. See acast.com/privacy for more information.

To mark Rare Disease Day on 29 February, Optimum Perspectives podcast interviews a panel of experts who discuss the opportunities and challenges for developers of therapies for rare diseases in 2024. 
Hosted on Acast. See acast.com/privacy for more information.

In this Optimum Perspectives celebratory episode for International Day of Women & Girls in Science, hear from five influential women on how they broke down gender barriers to succeed in the life science industry.
Chaired by esteemed journalist Lisa Urquhart, hear guest speakers Renee Aguiar-Lucander of Calliditas, Lene Gerlach of EIR Ventures & WiLD, Bita Sehat of Trill Impact, and Ninna Struck Rossen of Metsystem, share their stories on being women in life sciences, and how to succeed in the industry.

Hosted on Acast. See acast.com/privacy for more information.

Happy 1st birthday to the Optimum Perspectives Podcast! Since launching, 1000s of listens have grown the show into an excellent hub of intel from top tier life science guests. Listen now to our anniversary special, where Optimum's Mary Clark, Nick Bastin and Eva Haas discuss the findings of our insightful European Life Sciences Investor survey!
Hosted on Acast. See acast.com/privacy for more information.

Hear Vicore Pharma’s CEO, Ahmed Mousa speak to Optimum's Richard Staines on their new treatment for Idiopathic Pulmonary Fibrosis (IPF), C21. It aims to improve available treatments for patients of IPF by halting the progression of fibrosis and has the aim of restoring lung function.


Hosted on Acast. See acast.com/privacy for more information.